Analytical Data
-
Gene name
SLCO1B2
- Application
-
Alternative Names
Oatp1b2; Slc21a10; SLC21A6; LST-1; Liver-Specific Organic Anion Transporter 1; Solute Carrier Family 21 Member 10
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9JJL3
-
Expression Region
Phe421~Tyr533
-
Molecular Weight
16kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLCO1B2, a member of the solute carrier organic anion transporter family, plays a crucial role in the hepatic uptake of various endogenous compounds and pharmaceuticals, including statins and anti-cancer drugs. Given its significant influence on drug pharmacokinetics and safety, understanding the function and regulation of SLCO1B2 has become a key focus in both pharmacology and toxicology research. Dysregulation or genetic polymorphisms in SLCO1B2 can lead to altered drug metabolism and interindividual variability in drug response, which may increase the risk of adverse effects or therapeutic failure. Recent advances in recombinant protein technology have enabled researchers to produce and study SLCO1B2 in vitro, facilitating a more detailed examination of its substrate specificity, transport mechanisms, and potential interactions with various inhibitors. Investigating the structural and functional characteristics of SLCO1B2 through reconstitution into artificial membranes provides insights that can aid in predicting drug-drug interactions and optimizing therapeutic regimens. The findings from such studies may ultimately contribute to personalized medicine approaches, informing clinicians about the best drug choices and dosages for individual patients based on their SLCO1B2 genotype and expression levels. Therefore, continuous research on SLCO1B2 recombinant proteins holds promise for enhancing our understanding of drug transport processes and improving clinical outcomes in the management of diseases treated with various pharmacotherapeutics.
